NorthCrest Asset Manangement’s Vanda Pharmaceuticals VNDA Stock Holding History

NorthCrest Asset Manangement’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82.6K	Buy	+12,946	New	+$84.6K	﹤0.01%	897

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NorthCrest Asset Manangement's VNDA Position: Q2 2026 in Review

NorthCrest Asset Manangement opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 12,946 shares worth $82.6K. The stake represents ﹤0.01% of the portfolio and ranks #897 among its holdings.

172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

NorthCrest Asset Manangement held 12,946 shares of Vanda Pharmaceuticals worth $82.6K as of Q2 2026.
Vanda Pharmaceuticals was a new NorthCrest Asset Manangement position in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #897 holding.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.